Clinical significance of AR-V567Es in prostate cancer-response

Scott T. Tagawa, Emmanuel S. Antonarakis, Ada Gjyrezi, Giuseppe Galletti, Paraskevi Giannakakou

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)6010-6011
Number of pages2
JournalClinical Cancer Research
Issue number19
StatePublished - Oct 1 2019
Externally publishedYes

Bibliographical note

Funding Information:
S.T. Tagawa reports receiving commercial research grants from Sanofi, Janssen, Astellas, Pfizer, and Bayer, and is a consultant/advisory board member for Sanofi, Astellas, Bayer, and Janssen. E.S. Antonarakis holds ownership interest (including patents) in Qiagen. No potential conflicts of interest were disclosed by the other authors.

Cite this